TAPI-1 | CAS#171235-71-5 APExBIO 貨號 B4686
| 代理廠牌： |  |
| 原廠連結： | |
| 相關下載： |
特點
腫瘤壞死因子抑制劑系列商品->>TAPI-1
APExBIO Technology LLC 是一家領先的小分子抑制劑 (Small Molecule Inhibitors)/活化劑(Activators)、化合物庫( Compound Libraries)、胜肽(Peptides)、檢測試劑盒(Assay Kits)、螢光標記(Fluorescent Label)、酶(Enzymes)、修飾核苷酸(Modified Nucleotides)、mRNA 合成以及各種分子生物學工具的供應商。APExBIO提供廣泛的產品線，涵蓋 20 多個不同的研究領域，例如癌症(cancer)、免疫學(immunology)、神經科學(neurosciences)、細胞凋亡(apoptosis)和表觀遺傳學(epigenetics)等。公司總部位於美國德州休士頓USA (Houston, Texas)，致力於服務全球客戶。高度重視產品品質。所有產品均遵循嚴格的生產指南，並附有分析證書、HPLC、質譜(Mass Spectrum)和HMNR以及體外驗證(in vitro validation)。 APExBIO產品已被《Nature》、《Cell》和《Science》等眾多頂級同行評審期刊引用。>>更多APExBio商品
蛋白酶(Proteases)也稱為肽酶(peptidases)或蛋白水解酶(proteolytic enzymes)，由大量催化肽鍵水解(hydrolysis)並隨後導致蛋白質底物(protein substrates)降解為氨基酸(amino acids)的酶組成。蛋白酶(Proteases)與多種人類疾病有關，包括癌症(cancer)、神經退行性疾病(neurodegenerative disorders)、炎症性疾病(inflammatory diseases)和心血管疾病(cardiovascular diseases)。因此，許多蛋白酶抑制劑【小分子(small molecules)和蛋白質】已被鑑定為阻斷蛋白酶的活性(proteases)。蛋白酶抑制劑可以根據它們通過兩種一般機制抑制的蛋白酶類別分為不同的類型，即不可逆的“捕獲(trapping)”反應和可逆(reversible)的緊密結合反應。蛋白酶抑制劑已被用作治療蛋白酶相關疾病的診斷劑(diagnostic)或治療劑(therapeutic agents)。
TAPI-1 | CAS#171235-71-5 APExBIO 貨號 B4686
TACE/ADAM17 inhibitor Product Citation+3
TAPI-1 是一種腫瘤壞死因子抑制劑(Tumour necrosis factor)，IC50 值為 8.09 μM [1]。TAPI-1 是 TACE/ADAM17 的抑制劑，可催化全長 APP 裂解為可溶性 N 端片段 (sAPPα)。據報導，sAPPα 的釋放是通過刺激毒蕈鹼受體(muscarinic receptors)而增加的受體偶聯過程(receptor-coupled process)。在 HEK293 細胞中，TAPI-1 的處理導致抑制由 M3 亞型表達誘導的增加的 sAPPα。 TAPI-1抑制M3增加的sAPPα和sAPPα組成型釋放的IC50值分別為3.61 μM和8.09 μM。除 APP 外，還發現 TAPI-1 對 TNF-α、IL6R、TNFRI 和 TNFRII 的釋放具有抑制作用，IC50 值分別為 50-100、5-10、5-10 和 25-50 mM [1 , 2]。
- Zhang Y, Wang Y, et al. “Angiotensin Ⅱ deteriorates advanced atherosclerosis by promoting MerTK cleavage and impairing efferocytosis through AT1R/ROS/p38MAPK/ADAM17 pathway.” Am J Physiol Cell Physiol. 2019 Aug 7.PMID:31390228
- Zhou J, Sun J, et al. “MicroRNA-145 overexpression attenuates apoptosis and increases matrix synthesis in nucleus pulposus cells.” Life Sci. 2019 Mar 15;221:274-283.PMID:30797016
- Ellis-Connell AL, Balgeman AJ, et al. “ALT-803 transiently reduces SIV replication in the absence of antiretroviral treatment.” J Virol. 2017 Nov 8. pii: JVI.01748-17.PMID:29118125
| Physical Appearance | A solid |
| Storage | Store at -20°C |
| M.Wt | 499.6 |
| Cas No. | 171235-71-5 |
| Formula | C26H37N5O5 |
| Solubility | ≥24.98 mg/mL in DMSO; ≥15.77 mg/mL in EtOH with ultrasonic; ≥18.1 mg/mL in H2O |
| Chemical Name | N1-((R)-1-(((R)-1-((2-aminoethyl)amino)-1-oxopropan-2-yl)amino)-3-(naphthalen-2-yl)-1-oxopropan-2-yl)-N4-hydroxy-2-isobutylsuccinamide |
| SDF | Download SDF |
| Canonical SMILES | NCCNC([C@@H](C)NC([C@H](NC(C(CC(C)C)CC(NO)=O)=O)CC1=CC2=CC=CC=C2C=C1)=O)=O |
| Shipping Condition | Ship with blue ice, or upon other requests. |
| General tips | For obtaining a higher solubility, please warm the tube at 37°C and shake it in the ultrasonic bath for a while. We do not recommend long-term storage for the solution, please use it up soon. |
APExBIO台灣代理商: https://www.apexbt.com/
APExBIO提供優質的胜肽和生物分析試劑，廣泛產品線如Protease、Chromatin/Epigenetics表觀遺傳學、MAPK Signal、DNA Damege/DNA repair、細胞凋亡、腫瘤生物學、Stem cell等研究領域， 還提供定制的服務，包括多肽合成，抗體的生產和檢測的發展。產品線DNA/RNA prep kit、Drug Screening panel、Bioactive peptides、Growth factors、Biotinylation Reagents、tag peptides、amino Acids、Growth factors等。APExBIO產品質量都伴隨著證書的分析，高效液相色譜，質譜，和HMNR數據。
| 品項 | CAS# | #貨號 | 應用 |
| Z-VAD-FMK | CAS# 187389-52-2 | 貨號 A1902 |
Proteases ICE-like proteases |
| TAPI-1 | CAS#171235-71-5 | 貨號 B4686 |
Proteases TACE/ADAM17 inhibitor Product Citation+3 |
| Talabostat mesylate | CAS# 150080-09-4 | 貨號B3941 |
Proteases DPP4 二肽基肽酶特異性抑制劑 |
| Z-IETD-FMK | CAS# 210344-98-2 | 貨號B3232 | inhibitor of caspase 8 |
| Cisplatin | CAS# 15663-27-1 | 貨號A8321 | 高效、廣譜的化療藥物 |
| 17-DMAG (Alvespimycin) HCl | CAS#467214-21-7 | 貨號A2213 | Hsp90 inhibitor |
| CA-074 Me | CAS# 147859-80-1 | 貨號A8239 | Cathepsin B inhibitor |
| VX-765 | CAS# 273404-37-8 | 貨號A8238 | Caspase-1 inhibitor |
| A3608 | MK 0893 | 870823-12-4 | 98.58% | Glucagon receptor/IGF-1R antagonist |
| A3609 | MK-0591 | 136668-42-3 | 98.00% | FLAP inhibitor,potent and selective |
| A3611 | MK-0812 | 624733-88-6 | 98.00% | antagonist of chemokine receptor CCR-2 |
| A3612 | MK-0974 | 781649-09-0 | 98.00% | CGRP receptor antagonist |
| A3613 | MK-2894 | 1006036-87-8 | 98.00% | EP4 receptor inhibitor |
| A3615 | MK-3207 | 957118-49-9 | 98.00% | CGRP receptor antagonist |
| A3617 | MK-4827 | 1038915-60-4 | 98.93% | PARP-1/-2 inhibitor,potent and selective |
| A3618 | MK-5172 | 1350514-68-9 | 99.79% | HCV NS3/4a protease inhibitor |
| A3619 | MK-5172 hydrate | 1350462-55-3 | 98.00% | HCV NS3/4a protease inhibitor |
| A3620 | MK-5172 potassium salt | 1206524-86-8 | 98.00% | HCV NS3/4a protease inhibitor |
| A3621 | MK-5172 sodium salt | 1425038-27-2 | 98.00% | HCV NS3/4a protease inhibitor |
| A3623 | MK-6892 | 917910-45-3 | 99.65% | Highly potential GPR109A agonist |
| A3624 | MK-8033 | 1001917-37-8 | 98.00% | C-MET inhibitor |
| A3626 | ML-7 hydrochloride | 110448-33-4 | 98.43% | Myosin light chain kinase inhibitor |
| A3627 | MLN 2480 | 1096708-71-2 | 98.99% | Pan-Raf kinase inhibitor,investigational |
| A3628 | MLN120B | 783348-36-7 | 99.82% | IκB Kinase β Inhibitor |
| A3629 | MLN4924 HCl salt | 1160295-21-5 | 98.00% | NAE inhibitor |
| A3630 | MMAD | 203849-91-6 | 98.00% | Tubulin inhibitor,highly potent |
| A3631 | Monomethyl auristatin E | 474645-27-7 | 98.34% | Antimitotic agent |
| A3632 | Motesanib | 453562-69-1 | 98.00% | Inhibitor of Flk-1/Flt-4/PDGFR-/c-Kit |
| A3633 | MPEP Hydrochloride | 219911-35-0 | 98.00% | MGlu5 receptor antagonist |
| A3634 | MPTP hydrochloride | 23007-85-4 | 99.79% | Dopaminergic neurotoxin,induced reduction in the DOPAC HVA/dopamine (DA) ratio |
| A3636 | MTEP hydrochloride | 1186195-60-7 | 98.00% | MGlu5 antagonist |
| A3637 | GDC-mTOR inhibitor | 1207358-59-5 | 98.00% | MTOR inhibitor |
| A3641 | Naphthoquine phosphate | 173531-58-3 | 98.00% | Antimalarial drug |
| A3642 | Narciclasine | 29477-83-6 | 98.00% | Modulates the Rho/ROCK/LIM kinase/cofilin pathway |
| A3643 | Narlaprevir | 865466-24-6 | 98.00% | HCV NS3 protease inhibitor |
| A3645 | NB-598 | 131060-14-5 | 99.35% | SE inhibitor |
| A3646 | NB-598 hydrochloride | 136719-25-0 | 98.00% | SE inhibitor |
| A3647 | NB-598 Maleate | 155294-62-5 | 98.97% | Squalene epoxidase inhibitor |
| A3649 | NBD-556 | 333353-44-9 | 98.00% | HIV-1 entry inhibitor,CD4 mimetic,block gp120-CD4 interaction |
| A3652 | Necrostatin 2 | 852391-19-6 | 98.00% | In vitro necroptosis inhibitor |
| A3653 | Nelfinavir Mesylate | 159989-65-8 | 98.04% | HIV protease inhibitor,antiretroviral drug for HIV treatment |
| A3655 | Nesbuvir | 691852-58-1 | 99.79% | NS5B polymerase inhibitor |
| A3658 | NG25 | 1315355-93-1 | 98.00% | TAK1 inhibitor |
| A3659 | Nifuratel | 4936-47-4 | 98.00% | Antibacterial, antifungal, and antiprotozoal compound |
| A3660 | Nilotinib monohydrochloride monohydrate | 923288-90-8 | 99.89% | Bcr-Abl inhibitor |
| A3662 | NNC 55-0396 | 357400-13-6 | 98.00% | T-type calcium channel blocker |
| A3663 | Noopept | 157115-85-0 | 98.00% | Nootropic and neuroprotective agent |
| A3664 | Nordihydroguaiaretic acid | 500-38-9 | 99.83% | Anti-tumor agent;lipoxygenase inhibitor |
| A3665 | Nortadalafil | 171596-36-4 | 98.00% | PDE5 inhibitor |
| A3666 | NP118809 | 41332-24-5 | 98.00% | N-type calcium channel blocker |
| A3667 | NPS-2143 hydrochloride | 324523-20-8 | 99.89% | Calcium ion-sensing receptor antagonist |
| A3668 | NS309 | 18711-16-5 | 98.00% | Calcium-Activated Potassium Channel activator |
| A3670 | Nucleozin | 341001-38-5 | 99.55% | Targets influenza A nucleoprotein (NP),cell-permeable isoxazolylpiperazine compound |
| A3671 | Nutlin-3a chiral | 675576-98-4 | 98.39% | MDM2 inhibitor, antiproliferative and antiproapoptotic |
| A3672 | NVP-BAG956 | 853910-02-8 | 98.00% | PI3K and PDK1 inhibitor |
| A3673 | NVP-BGJ398 phosphate | 1310746-10-1 | 99.78% | FGFR inhibitor |
| A3674 | NVP-BKM120 Hydrochloride | 1312445-63-8 | 98.02% | PI3K inhibitor |
| A3675 | NVP-BSK805 | 1092499-93-8 | 98.00% | ATP-competitive JAK2 inhibitor |
| A3676 | NVP-LCQ195 | 902156-99-4 | 97.50% | CDK1/CDK2/CDK5 inhibitor |
| A3680 | Olcegepant | 204697-65-4 | 97.46% | Non-peptide receptor of CGRP,first potent and selective |
| A3681 | Olmesartan | 144689-24-7 | 99.20% | Angiotensin II receptor antagonist |
| A3683 | Olprinone Hydrochloride | 119615-63-3 | 99.74% | Phosphodiesterase 3 (PDE3) inhibitor, selective |
| A3684 | ONO-AE3-208 | 402473-54-5 | 97.73% | EP4 receptor antagonist,high affinity and selective |
| A3686 | Orteronel | 566939-85-3 | 98.00% | For castration-resistant prostate cancer, clinical candidate |
| A3688 | Oseltamivir | 196618-13-0 | 96.83% | inhibitor of influenza neuraminidase |
| A3689 | Oseltamivir acid | 187227-45-8 | 99.08% | Influenza neuraminidase inhibitor |
| A3690 | Otamixaban | 193153-04-7 | 98.00% | Direct factor Xa inhibitors,potent and selective |
| A3691 | Otenabant | 686344-29-6 | 98.00% | CB1 receptor antagonist |
| A3692 | OTX-015 | 202590-98-5 | 99.57% | BRD inhibitor |
| A3695 | Pafuramidine | 186953-56-0 | 98.00% | Prodrug of furamidine |
| A3696 | Palifosfamide | 31645-39-3 | 98.00% | Active metabolite of ifosfamide (IFOS) |
| A3697 | Palonosetron | 135729-61-2 | 98.00% | 5-HT3 antagonist |
| A3700 | Paradol | 27113-22-0 | 98.00% | Active flavor constituent of the seeds of Guinea pepper |
| A3702 | Paricalcitol | 131918-61-1 | 98.00% | Analog of VD2 active form |
| A3704 | PD 123319 ditrifluoroacetate | 136676-91-0 | 99.14% | Angiotensin AT2 receptor antagonist |
| A3706 | PDK1 inhibitor | 1001409-50-2 | 98.00% | PDK1 inhibitor |
| A3707 | Pemetrexed disodium hemipenta hydrate | 357166-30-4 | 99.94% | Antifolate and antimetabolite agent |
| A3708 | Pentostatin | 53910-25-1 | 99.05% | Irreversible adenosine deaminase inhibitor |
| A3709 | Peramivir | 330600-85-6 | 99.01% | Aeuraminidase inhibitor;antiviral drug |
| A3711 | PF-03084014 | 865773-15-5 | 98.52% | γ-secretase inhibitor |
| A3712 | PF-04217903 methanesulfonate | 956906-93-7 | 98.00% | C-Met inhibitor,selective and ATP-competitive |
| A3715 | PF-04971729 | 1210344-57-2 | 98.00% | SGLT inhibitor |
| A3716 | PF-3758309 | 898044-15-0 | 98.39% | PAK4 inhibitor |
| A3717 | PF-543 | 1415562-82-1 | 99.32% | SphK1 inhibitor,cell-permeate,potent and selective |
| A3718 | PF-543 Citrate | 1415562-83-2 | 98.95% | SphK1 inhibitor,potent and cell-permeate |
| A3719 | PF-670462 | 950912-80-8 | 99.66% | CK1 ε/δ inhibitor |
| A3720 | PF-8380 | 1144035-53-9 | 98.23% | Autotaxin inhibitor,potent and specific |
| A3721 | PHA-767491 | 845714-00-3 | 99.03% | Cdc7/cdk9 inhibitor, potent, ATP-competitive |
| A3722 | Phenylpiracetam | 77472-70-9 | 99.21% | Nootropic derivative of piracetam |
| A3723 | Phloretin | 60-82-2 | 99.12% | A dihydrochalcone found in apple |
| A3724 | PI-103 Hydrochloride | 371935-79-4 | 98.00% | DNA-PK/PI 3-kinase/mTOR inhibitor |
| A3727 | Pitolisant hydrochloride | 903576-44-3 | 99.71% | Nonimidazole inverse agonist |
| A3729 | PJ34 | 344458-19-1 | 95.69% | PARP-l inhibitor |
| A3730 | PND-1186 | 1061353-68-1 | 99.75% | Potent FAK inhibitor |
| A3732 | Poloxin | 321688-88-4 | 98.00% | PLK1 inhibitor |
| A3733 | Pramipexole dihydrochloride | 104632-25-9 | 98.94% | Dopamine receptor agonist |
| A3735 | Preladenant | 377727-87-2 | 98.00% | Adenosine A2A receptor antagonist |
| A3736 | PRT062607 Hydrochloride | 1370261-97-4 | 98.63% | SYK inhibitor,potent and selective |
| A3738 | PSI-7977 | 1190307-88-0 | 99.81% | Antiviral agents for chronic HCV infection |
| A3740 | Puromycin aminonucleoside | 58-60-6 | 98.19% | Aminonucleoside portion of the antibiotic puromycin |
| A3741 | Pyridone 6 | 457081-03-7 | 99.60% | Pan-JAK inhibitor |
| A3742 | Pyridostatin | 1085412-37-8 | 98.02% | Drug used for promoting growth arrest |
| A3744 | Quetiapine | 111974-69-7 | 98.00% | Dopamine receptor antagonist |
| A3746 | R1530 | 882531-87-5 | 98.00% | Antiangiogenesis,mitosis-angiogenesis inhibitor (MAI) |
| A3747 | R-7128 | 940908-79-2 | 98.00% | NS5B inhibitor |
| A3749 | Radezolid | 869884-78-6 | 99.32% | Novel oxazolidinone antibiotic agent |
| A3750 | Regorafenib hydrochloride | 835621-07-3 | 98.57% | Tyrosine kinase inhibitor |
| A3752 | Reparixin | 266359-83-5 | 98.11% | Inhibitor of CXCL8 receptor and CXCR1/CXCR2 activation |
| A3753 | Reparixin L-lysine salt | 266359-93-7 | 97.82% | CXCR1/CXCR2 inhibitor |
| A3754 | RepSox | 446859-33-2 | 99.83% | ALK5 inhibitor,potent and selective |
| A3755 | Resminostat hydrochloride | 1187075-34-8 | 98.00% | HDAC inhibitor |
| A3756 | Retaspimycin | 857402-23-4 | 98.00% | HSP90 inhibitor,antiproliferative and antineoplastic |
| A3758 | Retigabine dihydrochloride | 150812-13-8 | 99.27% | Antiepileptic compound |
| A3759 | Retinyl glucoside | 136778-12-6 | 98.00% | Metabolites of vitamin A |
| A3760 | Reversine | 656820-32-5 | 99.09% | A3 adenosine receptor antagonist,ARK-1/-2/-3 inhibitor |
| A3761 | RG2833 | 1215493-56-3 | 98.06% | Brain-penetrant HDAC inhibitor |
| A3762 | RG7112 | 939981-39-2 | 98.58% | MDM2 inhibitor, first clinical |
| A3763 | RG7388 | 1229705-06-9 | 99.82% | MDM2 antagonist, oral, selective |
| A3764 | RI-1 | 415713-60-9 | 99.54% | RAD51 inhibitor,cell-permeable |
| A3765 | Rilpivirine | 500287-72-9 | 99.64% | Inhibitor of next-generation nonnucleoside reverse transcriptase |
| A3766 | Rimonabant hydrochloride | 158681-13-1 | 98.01% | CB1 receptor inverse agonist |
| A3767 | Riociguat | 625115-55-1 | 99.77% | Soluble guanylate cyclase (sGC) stimulator |
| A3768 | Rivastigmine | 123441-03-2 | 99.68% | Cholinesterase inhibitor |
| A3770 | RJR-2403 oxalate | 220662-95-3 | 98.00% | Nicotinic receptor agonist |
| A3771 | RKI-1447 | 1342278-01-6 | 99.52% | Potent ROCK1/ROCK2 inhibitor |
| A3776 | Rotigotine | 99755-59-6 | 98.00% | Agonist of dopamine D2/D3 receptor |
| A3777 | Rotigotine hydrochloride | 125572-93-2 | 98.00% | Agonist of dopamine D2/D3 receptor |
| A3778 | RS 127445 | 199864-87-4 | 98.01% | 5-HT2B receptor antagonist,high affinity |
| A3780 | RU 58841 | 154992-24-2 | 98.40% | Androgen receptor antagonist |
| A3781 | Ruxolitinib phosphate | 1092939-17-7 | 98.75% | JAK1/JAK2 inhibitor |
| A3783 | S0859 | 1019331-10-2 | 98.00% | NBC inhibitor,potent and selective |
| A3784 | Safinamide | 133865-89-1 | 99.64% | MAO-B inhibitor |
| A3787 | Salirasib | 162520-00-5 | 99.28% | Inhibitor of active Ras protein |
| A3789 | Salmeterol xinafoate | 94749-08-3 | 98.11% | β2-adrenergic receptor agonist |
| A3790 | Saquinavir | 127779-20-8 | 98.00% | HIV Protease Inhibitor |
| A3791 | Saquinavir mesylate | 149845-06-7 | 99.75% | HIV Protease Inhibitor |
| A3792 | SB 239063 | 193551-21-2 | 98.63% | P38 MAP kinase inhibitor |
| A3794 | SB1317 | 937270-47-8 | 98.02% | CDK,JAK and FLT inhibitor |
| A3795 | SB-222200 | 174635-69-9 | 98.86% | Human NK-3 receptor antagonist |
| A3798 | SB-408124 Hydrochloride | 1431697-90-3 | 98.00% | OX1 receptor antagonist,selective and non-peptide |
| A3800 | SB-674042 | 483313-22-0 | 98.00% | OX1 selective antagonist |
| A3802 | SCH 527123 | 473727-83-2 | 99.40% | CXCR1 and CXCR2 receptors antagonist |
| A3804 | SCH-1473759 | 1094069-99-4 | 98.00% | Aurora A/B inhibitor |
| A3805 | SCH772984 | 942183-80-4 | 98.06% | ERK1 and ERK2 inhibitor |
| A3806 | SCH900776 S-isomer | 891494-64-7 | 99.18% | Checkpoint kinase(Chk)inhibitor |
| A3808 | SD-208 | 627536-09-8 | 99.11% | TGF-βR I kinase inhibitor |
| A3809 | SDZ 220-581 | 174575-17-8 | 98.00% | NMDA glutamate receptor subtype antagonist |
| A3811 | SEA0400 | 223104-29-8 | 99.20% | Specific inhibitor of Na+/Ca2+ exchange |
| A3814 | Seocalcitol | 134404-52-7 | 98.00% | Vitamin D receptor agonist |
| A3815 | Setiptiline | 57262-94-9 | 98.00% | Serotonin receptor antagonist |
| A3816 | Setiptiline maleate | 85650-57-3 | 98.00% | Serotonin receptor antagonist |
| A3818 | Silvestrol | 697235-38-4 | 98.00% | Antineoplastic |
| A3820 | Simeprevir | 923604-59-5 | 99.42% | Inhibitor of HCV NS3/4A protease |
| A3821 | SRT2104 (GSK2245840) | 1093403-33-8 | 98.50% | SIRT1 activator,selective |
| A3823 | SJB2-043 | 63388-44-3 | 99.78% | USP1 inhibitor |
| A3824 | Skepinone-L | 1221485-83-1 | 99.88% | P38-MAPK inhibitor,potent and selective |
| A3825 | SLx-2119 | 911417-87-3 | 98.80% | Selective ROCK2 inhibitor |
| A3826 | SMIP004 | 143360-00-3 | 98.17% | Apoptosis inducer |
| A3828 | Sobetirome | 211110-63-3 | 99.01% | Agonist of tyroid hormone receptor |
| A3829 | sodium 4-pentynoate | 101917-30-0 | 98.00% | chemical reporter for the profiling of acetylated proteins |
| A3832 | Solasodine | 126-17-0 | 98.00% | Neuroprotective antioxidant glycoalkaloid |
| A3834 | SQ109 | 502487-67-4 | 98.00% | Antibiotic for treatment of pulmonary TB |
| A3835 | SR1078 | 1246525-60-9 | 98.65% | Orphan receptor agonist |
| A3836 | SR3335 | 293753-05-6 | 99.52% | RORα agonist,partial inverse and selective |
| A3837 | DL-α-Hydroxyglutaric acid disodium salt | 40951-21-1 | 98.00% | alpha hydroxy acid |
| A3838 | SRT3109 | 1204707-71-0 | 98.00% | CXCR2 ligand |
| A3839 | SRT3190 | 1204707-73-2 | 99.56% | CXCR2 ligand,SIRT1 activator |
| A3840 | ST 2825 | 894787-30-5 | 98.00% | Inhibitor of MyD88 dimerization |
| A3843 | SU 5402 | 215543-92-3 | 98.48% | VEGFR2/FGFR/PDGFR/EGFR inhibitor |
| A3844 | SU14813 | 627908-92-3 | 98.00% | Tyrosine kinase inhibitor |
| A3846 | SU14813 maleate | 849643-15-8 | 98.00% | VEGFR/PDGFR/Kit/FLT-3 inhibitor |
| A3847 | SU5416 | 204005-46-9 | 99.06% | VEGF receptor inhibitor and AHR agonist |
| A3848 | Tacalcitol | 57333-96-7 | 98.00% | Promotes normal bone development by regulating calcium |
| A3850 | TAK-242 | 243984-11-4 | 99.53% | TLR 4 signaling inhibitor |
| A3853 | Talarozole | 201410-53-9 | 98.00% | Cytochrome P450 inhibitor |
| A3854 | Talnetant | 174636-32-9 | 98.00% | NK3 receptor antagonist,potent and selective |
| A3856 | Tamibarotene | 94497-51-5 | 98.41% | RARα agonist |
| A3857 | Tanaproget | 304853-42-7 | 98.00% | Progesterone receptor agonist |
| A3858 | Taranabant | 701977-09-5 | 98.00% | Cannabinoid receptor type 1 inverse agonist |
| A3859 | Tariquidar methanesulfonate, hydrate | 625375-83-9 | 99.49% | P-glycoprotein inhibitor, potent and selective |
| A3860 | Tasquinimod | 254964-60-8 | 99.47% | Antiangiogenic and antineoplastic agent |
| A3861 | TBB | 17374-26-4 | 99.23% | Casein kinase-2 (CK2) inhibitor |
| A3862 | TC-DAPK 6 | 315694-89-4 | 98.00% | DAPK inhibitor |
| A3863 | Tedizolid | 856866-72-3 | 99.63% | Oxazolidinone for gram-positive infections |
| A3864 | Tegobuvir | 1000787-75-6 | 98.97% | HCV RNA replication inhibitor |
| A3865 | Teneligliptin hydrobromide | 906093-29-6 | 99.90% | Dipeptidyl peptidase-4 inhibitor |
| A3870 | TG 100801 | 867331-82-6 | 98.00% | Multi-kinase inhibitor |
| A3872 | TH-302 | 918633-87-1 | 98.40% | Hypoxia-activated prodrug,inhibits H460/HT29 cell growth |
| A3873 | Tianeptine | 66981-73-5; 72797-41-2 | 99.46% | 5-HT facilitator |
| A3874 | Tiotropium Bromide | 136310-93-5 | 99.39% | MAChR M antagonist |
| A3875 | Tipiracil hydrochloride | 183204-72-0 | 99.74% | Thymidine phosphorylase inhibitor |
| A3876 | Tipranavir | 174484-41-4 | 98.00% | HIV protease inhibitor |
| A3877 | Tirofiban hydrochloride monohydrate | 150915-40-5 | 99.46% | Glycoprotein IIb/IIIa inhibitor |
| A3878 | TMC353121 | 857066-90-1 | 98.00% | Potent RSV fusion inhibitor |
| A3879 | Toceranib | 356068-94-5 | 98.00% | c-Kit/VEGFR/PDGFR inhibtor |
| A3881 | Toll-like receptor modulator | 926927-42-6 | 98.00% | TLR antagonist |